Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

144/433 Matches for
“NAFLD”

“NAFLD” Clear all
  1. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.

    Munteanu M et al. · Aliment Pharmacol Ther · 2018 Match 100

    …non-alcoholic fatty liver disease (NAFLD) with results similar to those in…

    FibroTest Alcohol HBV HCV +1

  2. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study.

    Zelber-Sagi S et al. · Hepatology · 2008 Match 100

    …Three hundred forty-nine patients (52.7% men, 30.9% primary NAFLD

    SteatoTest Metabolic

  3. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.

    European Association for the Study of the Liver (EASL) et al. · Obes Facts · 2016 Match 100

    FibroTest SteatoTest Metabolic

  4. Noninvasive evaluation of NAFLD.

    Castera L et al. · Nat Rev Gastroenterol Hepatol · 2013 Match 99

    A common clinical concern in patients with NAFLD is whether they have…

    ActiTest FibroTest NashTest SteatoTest +1

  5. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.

    Munteanu M et al. · Aliment Pharmacol Ther · 2016 Match 99

    NAFLD scores (Bonferroni test P < 0.05). ### Conclusions In patients with NAFLD

    ActiTest FibroTest SteatoTest Metabolic

  6. Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society.

    Petroff D et al. · Dig Liver Dis · 2018 Match 99

    FibroTest Metabolic

  7. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.

    Festi D et al. · Aliment Pharmacol Ther · 2013 Match 98

    ### Background Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of…

    SteatoTest

  8. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.

    Vilar-Gomez E et al. · J Hepatol · 2018 Match 98

    …non-alcoholic fatty liver disease (NAFLD). Since liver biopsy is invasive, expensive…

    FibroTest Metabolic

  9. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review

    Bril F et al. · Diabetes Care · 2017 Match 98

    Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…

    FibroTest Metabolic

  10. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

    Deckmyn O et al. · Biomedicines · 2022 Match 97

    In patients with non-alcoholic fatty liver disease (NAFLD) with or without…

    FibroTest Metabolic

  11. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.

    Adams LA et al. · J Gastroenterol Hepatol · 2011 Match 97

    …non-alcoholic fatty liver disease (NAFLD); however, it remains unclear whether non…

    FibroTest Metabolic

  12. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.

    Viglino D et al. · Eur Respir J · 2017 Match 97

    Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and…

    FibroTest NashTest SteatoTest Metabolic

  13. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.

    Pais R et al. · Eur J Intern Med · 2015 Match 96

    ### Unlabelled The association of NAFLD with chronic hepatitis C (CHC) has been…

    FibroTest SteatoTest HBV HCV +1

  14. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

    Lemoine M et al. · J Acquir Immune Defic Syndr · 2019 Match 96

    ### Background HIV-monoinfected individuals are at high risk of nonalcoholic fatty liver…

    FibroTest NashTest SteatoTest HIV

  15. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.

    Grattagliano I et al. · Ann Hepatol · 2013 Match 96

    …In conclusion, NAFLD should be systematically searched and characterized in all patients…

    ActiTest FibroTest NashTest SteatoTest +1

  16. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.

    Zelber-Sagi S et al. · Transl Res · 2015 Match 95

    Retrospective studies suggest that coffee consumption may exert beneficial effects in patients…

    FibroTest SteatoTest Metabolic

  17. The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.

    Netanel C et al. · Am J Surg · 2021 Match 95

    ### Background Nonalcoholic fatty liver disease (NAFLD) is common in bariatric surgery candidates…

    FibroTest NashTest SteatoTest Metabolic

  18. Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.

    Viglino D et al. · Sci Rep · 2018 Match 95

    Chronic Obstructive Pulmonary Disease (COPD) and Non-Alcoholic Fatty Liver Disease (NAFLD

    FibroTest NashTest SteatoTest Metabolic

  19. Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.

    Ciećko-Michalska I et al. · Arch Med Sci Atheroscler Dis · 2018 Match 94

    ### Introduction Nonalcoholic fatty liver disease (NAFLD) is one of the most common…

    ActiTest FibroTest SteatoTest Metabolic

  20. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication

    Munteanu M et al. · J Gastrointestin Liver Dis · 2008 Match 94

    ActiTest AshTest FibroTest NashTest +6

  21. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

    Zelber-Sagi S et al. · World J Gastroenterol · 2013 Match 94

    …The prevalence rate of NAFLD was 31.1% according to AUS. The…

    SteatoTest Metabolic

  22. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.

    Sberna AL et al. · Diabet Med · 2018 Match 93

    ### Aims To evaluate the application of the recently proposed recommendations by the…

    FibroTest NashTest Metabolic

  23. Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.

    Jullian-Desayes I et al. · Respirology · 2016 Match 93

    …non-alcoholic fatty liver disease (NAFLD) occurrence and progression. The impact of…

    NashTest SteatoTest Metabolic

  24. Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?

    Bush AM et al. · Aliment Pharmacol Ther · 2018 Match 93

    FibroTest Metabolic

  25. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.

    Harris R et al. · Lancet Gastroenterol Hepatol · 2017 Match 92

    As of 2016, there is no evidence-based pathway to stratify the…

    FibroTest Other

  26. Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.

    Minville C et al. · Chest · 2014 Match 92

    …In the same group, endothelial function and its links with NAFLD severity…

    FibroTest NashTest SteatoTest Metabolic

  27. The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.

    Simental-Mendía LE et al. · Ann Hepatol · 2016 Match 91

    …Given that early identification of non-alcoholic fatty liver disease (NAFLD) is…

    NashTest SteatoTest Metabolic

  28. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.

    Boursier J et al. · J Hepatol · 2016 Match 91

    ### Background & Aims NAFLD is highly prevalent but only a small subset of…

    FibroTest Metabolic

  29. Fibromax-based nonalcoholic fatty liver disease in chronic obstructive pulmonary disease patients with obstructive sleep apnea: Methodological considerations.

    Monneret D · F1000Res · 2017 Match 91

    The relationship between nonalcoholic fatty liver disease (NAFLD) and obstructive sleep apnea…

    FibroTest NashTest SteatoTest Metabolic

  30. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.

    Poynard T et al. · J Hepatol · 2012 Match 90

    …non-alcoholic fatty liver disease (NAFLD), and 218 with alcoholic fatty liver…

    FibroTest Alcohol HBV HCV +1

  31. Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.

    Meritsi A et al. · Clin Diabetes · 2022 Match 90

    ActiTest FibroTest NashTest-2 Metabolic

  32. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.

    Lassailly G et al. · Eur J Gastroenterol Hepatol · 2011 Match 90

    …Histology (NAFLD activity score, or NAFLD scoring system) and biochemical measurements were…

    FibroTest NashTest SteatoTest Metabolic

  33. Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.

    Denimal D et al. · Cardiovasc Diabetol · 2024 Match 89

    …However, it remains unclear whether NAFLD biomarkers could help estimate cardiovascular risk…

    ActiTest FibroTest NashTest SteatoTest +1

  34. Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.

    Boursier J et al. · Clin Gastroenterol Hepatol · 2023 Match 89

    ### Background & Aims Noninvasive tests (NITs) of liver fibrosis have been suggested to…

    FibroTest Metabolic

  35. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication

    Ratziu V et al. · BMC Gastroenterol · 2006 Match 89

    …patients with NAFLD. ### Methods 170 patients with suspected NAFLD were prospectively included…

    FibroTest Metabolic

  36. Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.

    de Lédinghen V et al. · Dig Liver Dis · 2012 Match 88

    ### Background Patients with diabetes are at risk for nonalcoholic fatty liver disease…

    FibroTest Metabolic

  37. Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis.

    Brener S · Ont Health Technol Assess Ser · 2015 Match 88

    ### Background Liver fibrosis is a sign of advanced liver disease and is…

    Elasto-FibroTest FibroTest Alcohol HBV +3

  38. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.

    Jacqueminet S et al. · Clin Gastroenterol Hepatol · 2008 Match 88

    ### Background & Aims Patients with diabetes are at risk for nonalcoholic fatty liver…

    FibroTest SteatoTest Metabolic

  39. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2019 Match 87

    …0.74-0.74) in presumed NAFLD to 0.91 (95% CI…

    NashTest-2 SteatoTest-2 Metabolic

  40. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015 Match 87

    FibroTest Alcohol HBV HCV +3

  41. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication

    Poynard T et al. · BMC Gastroenterol · 2006 Match 87

    …in patients with NAFLD. ### Methods 160 patients with NAFLD were prospectively included…

    NashTest Metabolic

  42. Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.

    Copaci I et al. · Rom J Intern Med · 2015 Match 86

    ### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance…

    SteatoTest Metabolic

  43. Meta-analyses of FibroTest diagnostic value in chronic liver disease.

    Poynard T et al. · BMC Gastroenterol · 2007 Match 86

    …non-alcoholic fatty liver disease (NAFLD); and the other, that the FT…

    FibroTest Alcohol HBV HCV +1

  44. Non-invasive markers for hepatic fibrosis.

    Baranova A et al. · BMC Gastroenterol · 2011 Match 86

    With great advancements in the therapeutic modalities used for the treatment of…

    FibroTest Alcohol HBV HCV +3

  45. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.

    Poynard T et al. · Aliment Pharmacol Ther · 2021 Match 85

    ### Background One of the unmet needs in patients with type 2 diabetes…

    FibroTest NashTest-2 SteatoTest Metabolic

  46. PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.

    Petit JM et al. · Liver Int · 2011 Match 85

    ### Context Recently, it has been shown that an allele in the adiponutrin…

    FibroTest Metabolic

  47. Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.

    Sebastiani G et al. · Can J Gastroenterol Hepatol · 2014 Match 85

    ### Objective To determine practices among physicians in Canada for the assessment of…

    FibroTest Alcohol HBV HCV +3

  48. Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis.

    Poynard T et al. · Clin Gastroenterol Hepatol · 2012 Match 84

    ### Background & Aims There is controversy about the performance of noninvasive tests such…

    FibroTest Alcohol HBV HCV +3

  49. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication

    Halfon P et al. · Gastroenterol Clin Biol · 2008 Match 84

    …non-alcoholic fatty liver disease (NAFLD). The primary aim of the present…

    FibroTest Alcohol HBV HCV +2

  50. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.

    de Lédinghen V et al. · Liver Int · 2012 Match 83

    …age 54 years, BMI 26 kg m(-) ², HCV 36%, NAFLD 25…

    SteatoTest Metabolic

  51. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.

    Perazzo H et al. · Aliment Pharmacol Ther · 2014 Match 83

    ### Background In cardiometabolic disorders, non-alcoholic fatty liver disease is frequent and…

    FibroTest SteatoTest Metabolic

  52. Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

    López Tórrez SM et al. · Front Nutr · 2024 Match 83

    ### Introduction A prognostic model to predict liver severity in people with metabolic…

    FibroTest Metabolic

  53. The non-invasive assessment of hepatic fibrosis.

    Gheorghe G et al. · J Formos Med Assoc · 2021 Match 82

    Hepatic disease accounts for approximately 2 million deaths/year worldwide. Liver fibrosis…

    ActiTest FibroTest Alcohol HBV +2

  54. Evolution of Non-alcoholic Fatty Liver Disease (NAFLD) Biomarkers in Response to Weight Loss 1 Year After Bariatric Surgery-a Post Hoc Analysis of the FibroTest Prospective Study.

    Codjia T et al. · Obes Surg · 2021 Match 82

    …The aim of this study was to evaluate the evolution of NAFLD

    FibroTest NashTest SteatoTest Metabolic

  55. Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study.

    Flores-Calderón J et al. · Ann Hepatol · 2012 Match 82

    ### Introduction Identifying liver fibrosis is important to evaluate the severity of liver…

    FibroTest

  56. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 81

    ### Background One of the unmet needs in patients with metabolic risks is…

    FibroTest NashTest SteatoTest Metabolic

  57. Noninvasive Assessment of Liver Fibrosis.

    Castera L · Dig Dis · 2015 Match 81

    ### Background The prognosis and management of chronic liver diseases greatly depend on…

    FibroTest HBV HCV

  58. Glycogenic hepatopathy.

    Khoury J et al. · Hepatobiliary Pancreat Dis Int · 2018 Match 81

    ### Background Glycogenic hepatopathy (GH) is a disorder associated with uncontrolled diabetes mellitus…

    FibroTest Metabolic

  59. Impact of steatosis and inflammation definitions on the performance of NASH tests.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 80

    ### Background And Aim One of the unmet needs in subjects with metabolic…

    ActiTest FibroTest NashTest NashTest-2 +3

  60. Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.

    Chiou YL et al. · J Am Coll Nutr · 2021 Match 80

    ### Objective Nonalcoholic steatohepatitis (NASH) has become a prominent liver disease in contemporary…

    ActiTest FibroTest SteatoTest Metabolic

  61. Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.

    Matta B et al. · Curr HIV/AIDS Rep · 2016 Match 80

    …such as HCV, HBV, and NAFLD. Identifying HIV-infected patients with significant…

    FibroTest HBV HCV HIV

  62. Dietary vitamin E and C intake is inversely associated with the severity of nonalcoholic fatty liver disease.

    Ivancovsky-Wajcman D et al. · Dig Liver Dis · 2019 Match 79

    …The presence of NAFLD was evaluated by ultrasonography. The level of steatosis…

    FibroTest NashTest SteatoTest Metabolic

  63. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.

    Bedossa P et al. · Hepatology · 2012 Match 79

    ### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and being overweight…

    Metabolic

  64. A Single Test Combining Blood Markers and Elastography is More Accurate Than Other Fibrosis Tests in the Main Causes of Chronic Liver Diseases.

    Ducancelle A et al. · J Clin Gastroenterol · 2017 Match 79

    …In NAFLD, CHC-specific tests were more accurate than NAFLD-specific tests…

    FibroTest Alcohol HBV HCV +2

  65. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.

    Poynard T et al. · PLoS One · 2012 Match 78

    …non-alcoholic fatty liver disease (NAFLD) histologic lesions in patients with severe…

    ActiTest FibroTest NashTest SteatoTest +1

  66. The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.

    Imbert-Bismut F et al. · Eur J Gastroenterol Hepatol · 2009 Match 78

    ### Background And Aim The validity of biomarkers of excessive alcohol drinking (EAD…

    FibroTest SteatoTest Alcohol

  67. FibroMAX: towards a new universal biomarker of liver disease?

    Morra R et al. · Expert Rev Mol Diagn · 2007 Match 78

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest AshTest FibroTest NashTest +7

  68. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).

    Poynard T et al. · BMC Gastroenterol · 2010 Match 77

    …nonalcoholic fatty liver disease (NAFLD) in 66%, NAFLD in 13%, alcohol in…

    FibroTest Alcohol HBV HCV +3

  69. Study of FibroTest and hyaluronic acid biological variation in healthy volunteers and comparison of serum hyaluronic acid biological variation between chronic liver diseases of different etiology and fibrotic stage using confidence intervals.

    Istaces N et al. · Clin Biochem · 2015 Match 77

    ### Objectives Personalized ranges of liver fibrosis serum biomarkers such as FibroTest or…

    FibroTest HBV HCV

  70. Noninvasive Testing for Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Patients With Psoriasis Receiving Long-term Methotrexate Sodium Therapy.

    Bauer B et al. · JAMA Dermatol · 2017 Match 77

    ### Importance The long-term implications of hepatotoxic effects in patients with psoriasis…

    FibroTest NashTest

  71. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.

    Younossi ZM et al. · Gastroenterology · 2021 Match 76

    …in F3 and for ELF, NAFLD Fibrosis Score, Fibrosis-4 (FIB-4…

    FibroTest Metabolic

  72. Assessment of liver fibrosis: noninvasive means.

    Poynard T et al. · Saudi J Gastroenterol · 2008 Match 76

    …HCV), B (HBV) non alcoholic (NAFLD) and alcoholic (ALD) fatty liver diseases…

    FibroTest Alcohol HBV HCV +3

  73. Pharmacotherapeutic efficacy on noninvasive fibrosis progression in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. Review

    Kovalic AJ et al. · Eur J Gastroenterol Hepatol · 2023 Match 75

    …with nonalcoholic fatty liver disease (NAFLD). Due to well-documented flaws associated…

    FibroTest Metabolic

  74. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.

    Canivet CM et al. · Hepatology · 2023 Match 75

    NAFLD). ### Approach And Results One thousand fifty-one patients with NAFLD, liver…

    FibroTest Metabolic

  75. Biomarkers of liver fibrosis.

    Poynard T et al. · Adv Clin Chem · 2008 Match 75

    …hepatitis nonalcoholic fatty liver disease (NAFLD), and alcoholic liver disease (ALD). Neither…

    ActiTest FibroTest SteatoTest Alcohol +5

  76. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Comp Hepatol · 2005 Match 74

    ### Background Biopsy is the usual gold standard for liver steatosis assessment. The…

    SteatoTest Alcohol HBV HCV +1

  77. Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.

    Guiu B et al. · Eur Radiol · 2012 Match 74

    ### Objectives The SteatoTest, fatty liver index (FLI) and hepatic steatosis index (HSI…

    SteatoTest Metabolic

  78. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease.

    Munteanu M et al. · Aliment Pharmacol Ther · 2013 Match 74

    FibroTest Metabolic

  79. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.

    Poynard T et al. · PLoS One · 2008 Match 73

    …male gender, older age, and NAFLD as a cause of liver disease…

    FibroTest Alcohol HBV HCV +3

  80. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.

    Bril F et al. · Diabetes Care · 2020 Match 73

    …with nonalcoholic fatty liver disease (NAFLD) should be evaluated for liver fibrosis…

    FibroTest NashTest-2 Metabolic

  81. Response to: Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications, by Jerome Boursier et al.

    Poynard T et al. · Clin Gastroenterol Hepatol · 2023 Match 73

    FibroTest Metabolic

  82. Noninvasive diagnosis in alcohol-related liver disease. Review

    Hadefi A et al. · Health Sci Rep · 2020 Match 72

    …and nonalcoholic fatty liver disease (NAFLD), their performance in ALD has also…

    FibroTest Alcohol

  83. Silymarin in non alcoholic fatty liver disease.

    Cacciapuoti F et al. · World J Hepatol · 2013 Match 72

    …liver disease (NAFLD). ### Methods In 72 patients affected by NAFLD, main metabolic…

    SteatoTest Metabolic

  84. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy.

    Anastasiou J et al. · Eur J Gastroenterol Hepatol · 2010 Match 72

    ### Background The efficiency of transient elastography for the assessment of liver fibrosis…

    ActiTest FibroTest Alcohol HBV +3

  85. Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.

    Poinsot P et al. · J Clin Lipidol · 2017 Match 71

    ### Background The childhood/adult-onset lysosomal acid lipase deficiency (LALD; late-onset…

    FibroTest Metabolic

  86. Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.

    Poynard T et al. · PLoS One · 2016 Match 71

    ### Background And Aims Real-time shear wave elastography (2D-SWE) is a…

    ActiTest FibroTest SteatoTest Alcohol +3

  87. Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication

    Poynard T et al. · PLoS One · 2020 Match 71

    ### Background Since 1920, a decrease in serum cholesterol has been identified as…

    FibroTest COVID

  88. Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.

    Poynard T et al. · Hepatol Commun · 2023 Match 70

    ### Background And Aims Gilbert syndrome (GS) is genotypically predetermined by UGT1A1*28…

    FibroTest

  89. Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2020 Match 70

    ### Objective There is a controversy about the performance of blood tests for…

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  90. Reproducibility of blood tests of liver fibrosis in clinical practice.

    Calès P et al. · Clin Biochem · 2008 Match 70

    ### Objectives To evaluate the inter-laboratory reproducibility of blood test for liver…

    FibroTest Alcohol HBV HCV +1

  91. Applicability and variability of liver stiffness measurements according to probe position.

    Ingiliz P et al. · World J Gastroenterol · 2009 Match 69

    ### Aim To investigate the liver stiffness measurement (LSM) applicability and variability with…

    FibroTest Alcohol HBV HCV +3

  92. Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions.

    Mahamid M et al. · Clin Pharmacol · 2011 Match 69

    ### Background Elevation of liver enzymes in rheumatoid arthritis patients treated with tocilizumab…

    FibroTest Other

  93. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.

    Bril F et al. · J Investig Med · 2019 Match 69

    …non-alcoholic fatty liver disease (NAFLD) by ^1^H-MRS. For determination…

    ActiTest FibroTest NashTest SteatoTest +1

  94. Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

    Poynard T et al. · Diagnostics (Basel) · 2025 Match 68

    **Background/Objectives:** Bariatric surgery (BS), drugs approved for type-2-diabetes (T2D…

    FibroTest-T2D Metabolic

  95. Liver fibrosis markers in alcoholic liver disease.

    Chrostek L et al. · World J Gastroenterol · 2014 Match 68

    Alcohol is one of the main factors of liver damage. The evaluation…

    FibroTest Alcohol

  96. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.

    Thiele M et al. · Gastroenterology · 2018 Match 68

    ### Background & Aims Alcohol is the leading cause of cirrhosis and liver-related…

    FibroTest Alcohol

  97. Personalized management of cirrhosis by non-invasive tests of liver fibrosis.

    Wong GL et al. · Clin Mol Hepatol · 2015 Match 67

    Owing to the high prevalence of various chronic liver diseases, cirrhosis is…

    FibroTest Alcohol HBV HCV +1

  98. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review

    Moreno C et al. · J Hepatol · 2019 Match 67

    Even though alcohol-related liver disease (ALD) is a major cause of…

    FibroTest Alcohol

  99. Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

    Denimal D et al. · Cardiovasc Diabetol · 2025 Match 66

    ### Background Studies have demonstrated that both lower limb arterial calcification and metabolic…

    ActiTest FibroTest NashTest SteatoTest +1

  100. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.

    Ratziu V et al. · J Hepatol · 2011 Match 66

    ### Background & Aims Nonalcoholic steatohepatitis (NASH) is a prevalent liver disease associated with…

    FibroTest Metabolic

  101. Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

    Poynard T et al. · BMJ Open · 2015 Match 66

    ### Background Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement for…

    ActiTest FibroTest Alcohol HBV +3

  102. Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.

    Peta V et al. · PLoS One · 2017 Match 65

    ### Background There is a clear need for better biomarkers of drug-induced…

    ActiTest FibroTest Other

  103. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication

    Poynard T et al. · Gastroenterol Clin Biol · 2008 Match 65

    This review summarizes the methodological aspects of the interpretation of non-invasive…

    ActiTest FibroTest SteatoTest Alcohol +5

  104. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.

    Poynard T et al. · Aliment Pharmacol Ther · 2023 Match 65

    FibroTest-T2D NashTest-T2D SteatoTest-T2D Metabolic

  105. The risk of multiplying diagnostic combinations in the absence of a perfect gold standard for a fibrosis test.

    Munteanu M et al. · Am J Gastroenterol · 2011 Match 64

    FibroTest HCV

  106. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2019 Match 64

    ### Background No blood test has been shown to be effective in the…

    LCR1 LCR2 Alcohol HBV +4

  107. Management of the patient with SVR. Review

    Terrault NA et al. · J Hepatol · 2016 Match 64

    In the current era of therapy with direct-acting antiviral (DAAs) drugs…

    FibroTest HCV

  108. Prognostic value of liver fibrosis biomarkers: a meta-analysis.

    Poynard T et al. · Gastroenterol Hepatol (N Y) · 2011 Match 63

    ### Aims And Methods Several serum biomarkers such as FibroTest, aspartate transaminase-platelet…

    FibroTest Alcohol HBV HCV +3

  109. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis.

    Boursier J et al. · Liver Int · 2009 Match 63

    ### Background And Aims Blood tests and liver stiffness evaluation (LSE) by ultrasonographic…

    FibroTest Alcohol HBV HCV +2

  110. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?

    Poynard T et al. · Gastroenterology · 2005 Match 63

    ActiTest FibroTest Alcohol HBV +3

  111. Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.

    Poynard T et al. · J Hepatol · 2013 Match 62

    ### Background & Aims Real-time shear wave elastography (SWE) is a new two…

    FibroTest Alcohol HBV HCV +3

  112. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis.

    Golabi P et al. · Expert Rev Gastroenterol Hepatol · 2016 Match 62

    Nonalcoholic steatohepatitis (NASH) can lead to complications such as liver failure, cirrhosis…

    FibroTest Metabolic

  113. Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.

    Braha A et al. · J Clin Med · 2024 Match 62

    **Background/Objectives**: Prior research has identified a significant association between heart disease…

    FibroTest Metabolic

  114. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.

    Poynard T et al. · BMC Gastroenterol · 2011 Match 61

    ### Background FibroTest (FT) is a validated biomarker of fibrosis. To assess the…

    ActiTest FibroTest Alcohol HBV +4

  115. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication

    Shiha G et al. · Hepatol Int · 2009 Match 61

    Liver fibrosis is a common pathway leading to cirrhosis, which is the…

    FibroTest SteatoTest HBV HCV +1

  116. Screening studies of transient elastography and FibroTest in the general population.

    Poynard T et al. · Lancet Gastroenterol Hepatol · 2017 Match 61

    FibroTest Other

  117. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.

    Houot M et al. · Aliment Pharmacol Ther · 2016 Match 60

    ### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…

    FibroTest HBV HCV

  118. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.

    Festi D et al. · Aliment Pharmacol Ther · 2013 Match 60

    FibroTest Metabolic

  119. First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.

    Poynard T · J Hepatol · 2011 Match 60

    ActiTest AshTest FibroTest NashTest +7

  120. Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients.

    Crisan D et al. · Hepat Mon · 2012 Match 59

    ### Background The prediction of fibrosis is an essential part of the assessment…

    FibroTest HCV

  121. Screening studies of transient elastography and FibroTest in the general population - Authors' reply.

    Ginès P et al. · Lancet Gastroenterol Hepatol · 2017 Match 59

    FibroTest Other

  122. Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.

    Rudler M et al. · PLoS One · 2015 Match 58

    ### Background/Aims According to guidelines, the histological diagnosis of severe alcoholic steatohepatitis…

    AshTest Alcohol

  123. Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.

    Lombardi R et al. · World J Gastroenterol · 2015 Match 58

    Alcoholic liver disease (ALD) consists of a broad spectrum of disorders, ranging…

    FibroTest Alcohol

  124. Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.

    White DL et al. · J Clin Gastroenterol · 2012 Match 58

    ### Background African Americans have lower reported likelihood of hepatitis C virus-related…

    ActiTest FibroTest HCV

  125. Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest.

    El-Shabrawi MH et al. · Eur J Gastroenterol Hepatol · 2010 Match 57

    ### Background Hepatitis C virus (HCV) is a major cause of chronic hepatitis…

    ActiTest FibroTest HCV

  126. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?

    Poynard T et al. · Expert Rev Mol Diagn · 2005 Match 57

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest FibroTest Alcohol HBV +2

  127. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis.

    Poynard T et al. · Aliment Pharmacol Ther · 2019 Match 57

    ### Background No blood test has been shown to be effective in the…

    FibroTest LCR1 LCR2 Alcohol +3

  128. Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers.

    Patel K et al. · Aliment Pharmacol Ther · 2016 Match 56

    ### Background Assessment of fibrosis progression in chronic liver disease relies upon non…

  129. Noninvasive Indirect Markers of Liver Fibrosis in Alcoholics.

    Chrostek L et al. · Biomed Res Int · 2019 Match 56

    The aim of this study was to evaluate the diagnostic values of…

    FibroTest Alcohol

  130. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.

    Friedrich-Rust M et al. · J Clin Gastroenterol · 2010 Match 56

    ### Background In recent years noninvasive methods have been evaluated for the assessment…

    FibroTest SteatoTest Other

  131. Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest).

    Munteanu M et al. · Comp Hepatol · 2004 Match 55

    BACKGROUND: Biochemical marker combinations, including alpha2-macroglobulin, haptoglobin, apolipoprotein A1, gamma-glutamyl…

    ActiTest FibroTest Alcohol HBV +3

  132. Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis.

    Gressner OA et al. · Clin Chim Acta · 2009 Match 55

    ### Introduction Non-invasive, i.e. serum-based assessment of liver fibrosis is…

    ActiTest FibroTest HCV

  133. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection.

    Calès P et al. · J Hepatol · 2010 Match 55

    ### Background & Aims We compared 5 non-specific and 2 specific blood tests…

    FibroTest HCV HIV

  134. Assessment of Selected Parameters of Liver Fibrosis and Inflammation in Patients with Diagnosed Cystic Fibrosis.

    Więcek S et al. · Mediators Inflamm · 2020 Match 54

    Changes in the liver and bile ducts observed in patients diagnosed with…

    ActiTest FibroTest Other

  135. [Alpha 2 macroglobulin immunoturbidimetric assays (DakoCytomation reagents) on Roche Diagnostic analysers (Modular P, Cobas Integra). Application to FibroTest-Actic-Test].

    Piton A et al. · Ann Biol Clin (Paris) · 2005 Match 54

    ### Background Alpha2Macroglobulin (A2M) measure showed a revival since it was introduced into…

    ActiTest FibroTest

  136. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. Key publication

    Nguyen-Khac E et al. · Aliment Pharmacol Ther · 2008 Match 54

    ### Background Systematic screening for liver fibrosis in heavy-drinking patients is a…

    FibroTest Alcohol

  137. Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients.

    Beckebaum S et al. · Transplantation · 2010 Match 53

    ### Background This prospective, monocentric study was designed to assess the efficacy of…

    FibroTest Alcohol HBV HCV +2

  138. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.

    Poynard T et al. · Clin Chem · 2004 Match 53

    ### Background The FibroTest and ActiTest are noninvasive biochemical markers of liver injury…

    ActiTest FibroTest HCV

  139. Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

    Peta V et al. · World J Hepatol · 2025 Match 53

    ### Background Noninvasive tests are crucial for the management and follow-up of…

    ActiTest FibroTest AIH

  140. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.

    Poynard T et al. · Gastro Hep Adv · 2022 Match 52

    ### Background And Aims The liver cancer risk test (LCR1-LCR2) is a…

    FibroTest LCR1 LCR2 Surveillance-FibroTest +1

  141. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.

    Sebastiani G et al. · Aliment Pharmacol Ther · 2011 Match 52

    ### Background Performance of non-invasive fibrosis biomarkers may be influenced by aetiology…

    FibroTest HBV HCV HIV +1

  142. Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.

    Rhodes FA et al. · J Gastroenterol Hepatol · 2021 Match 52

    ### Background And Aim Mortality of alcohol-related liver disease (ArLD) is increasing…

    FibroTest Alcohol

  143. EASL clinical practical guidelines: management of alcoholic liver disease.

    European Association for the Study of Liver · J Hepatol · 2012 Match 51

    FibroTest Alcohol

  144. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.

    Stevenson M et al. · Health Technol Assess · 2012 Match 51

    ### Background Excessive alcohol consumption may lead to the development of alcohol-related…

    FibroTest Alcohol

Showing the full result list. The page is server-rendered and not paginated.